{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:44:24Z","timestamp":1791571464495,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejca.2018.06.032","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T12:55:29Z","timestamp":1532091329000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012"],"prefix":"10.1016","volume":"101","author":[{"given":"C.","family":"Schroten-Loef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.A.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.H.J.T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"van de Wouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.E.P.P.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2018.06.032_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jso.20099","article-title":"Unknown primary","volume":"87","author":"Chorost","year":"2004","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.06.032_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJM199307223290407","article-title":"Treatment of patients with cancer of an unknown primary site","volume":"329","author":"Hainsworth","year":"1993","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2018.06.032_bib3","first-page":"3403","article-title":"Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma","volume":"5","author":"Hess","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.critrevonc.2008.09.005","article-title":"Carcinoma of unknown primary (CUP)","volume":"69","author":"Pavlidis","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jare.2014.11.007","article-title":"A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists","volume":"6","author":"Pavlidis","year":"2015","journal-title":"J Adv Res"},{"issue":"7","key":"10.1016\/j.ejca.2018.06.032_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.ejca.2018.06.032_bib7","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2012.46.8371","article-title":"Critical evaluation of oncology clinical practice guidelines","volume":"31","author":"Reames","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.06.032_bib8","series-title":"Oncoline, Primaire tumor onbekend","year":"2012"},{"key":"10.1016\/j.ejca.2018.06.032_bib9","series-title":"Occult primary (Cancer of Unknown Primary [CUP])","author":"NCCN","year":"2015"},{"key":"10.1016\/j.ejca.2018.06.032_bib10","series-title":"Diagnosis and management of metastatic malignant disease of unknown primary origin","author":"NICE","year":"2010"},{"key":"10.1016\/j.ejca.2018.06.032_bib11","article-title":"International variation in diagnostic and treatment guidelines for carcinoma unknown primary","author":"Kok","year":"2015","journal-title":"Int J Cancer Res","ISSN":"https:\/\/id.crossref.org\/issn\/2051-784X","issn-type":"print"},{"issue":"7","key":"10.1016\/j.ejca.2018.06.032_bib12","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","article-title":"Survival in cancer of unknown primary site: population-based analysis by site and histology","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.06.032_bib13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/annonc\/mdp583","article-title":"Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy","volume":"21","author":"Kodaira","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.032_bib14","first-page":"297","article-title":"Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT","volume":"24","author":"van de Wouw","year":"2004","journal-title":"Anticancer Res"},{"issue":"9824","key":"10.1016\/j.ejca.2018.06.032_bib15","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.032_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/bjc.2013.683","article-title":"Inflammation as a validated prognostic determinant in carcinoma of unknown primary site","volume":"110","author":"Mohamed","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2018.06.032_bib17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ctrv.2013.03.001","article-title":"Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature","volume":"39","author":"Petrakis","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ejca.2018.06.032_bib18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12032-013-0706-5","article-title":"Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience","volume":"30","author":"Randen","year":"2013","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.032_bib19","doi-asserted-by":"crossref","first-page":"e6483","DOI":"10.1371\/journal.pone.0006483","article-title":"Development and validation of a bedside score to predict early death in cancer of unknown primary patients","volume":"4","author":"Penel","year":"2009","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejca.2018.06.032_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12094-007-0084-6","article-title":"Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables","volume":"9","author":"Ponce Lorenzo","year":"2007","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.06.032_bib21","first-page":"532","article-title":"Carcinoma of unknown primary site","volume":"27","author":"Seve","year":"2006","journal-title":"Rev Med Interne"},{"issue":"12","key":"10.1016\/j.ejca.2018.06.032_bib22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0399-8320(05)82205-5","article-title":"Hepatic metastases from carcinomas of unknown primary site","volume":"29","author":"Pouessel","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.ejca.2018.06.032_bib23","unstructured":"Oncology, I.C.o.D.f., ed. Geneva. vol. 3, 2000."},{"issue":"10","key":"10.1016\/j.ejca.2018.06.032_bib24","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00586-009-1061-2","article-title":"Diagnosis of a previously unidentified primary site in patients with spinal metastasis: diagnostic usefulness of laboratory analysis, CT scanning and CT-guided biopsy","volume":"18","author":"Iizuka","year":"2009","journal-title":"Eur Spine J"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.humpath.2009.09.001","article-title":"The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma","volume":"41","author":"Park","year":"2010","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2303.2007.00551.x","article-title":"Identification of carcinoma origin by thyroid transcription factor-1 immunostaining of fine needle aspirates of metastases","volume":"20","author":"Strojan Flezar","year":"2009","journal-title":"Cytopathology"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2018.06.032_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00292-009-1194-4","article-title":"Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification","volume":"30","author":"Morawietz","year":"2009","journal-title":"Pathologe"},{"issue":"2","key":"10.1016\/j.ejca.2018.06.032_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5858\/134.2.216","article-title":"Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin","volume":"134","author":"Monzon","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"10.1016\/j.ejca.2018.06.032_bib29","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/lary.21030","article-title":"New techniques to detect unknown primaries in cervical lymph node metastasis","volume":"120","author":"Sakai","year":"2010","journal-title":"Laryngoscope"},{"issue":"12","key":"10.1016\/j.ejca.2018.06.032_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1245\/ASO.2005.03.520","article-title":"Utility of breast magnetic resonance imaging in patients with occult primary breast cancer","volume":"12","author":"Buchanan","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2018.06.032_bib31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/MNM.0b013e328302cd26","article-title":"Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET\/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature","volume":"29","author":"Dong","year":"2008","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00330-008-1194-4","article-title":"Combined FDG-PET\/CT for the detection of unknown primary tumors: systematic review and meta-analysis","volume":"19","author":"Kwee","year":"2009","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.ejca.2018.06.032_bib33","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.ejca.2013.02.022","article-title":"Time trends in survival from cancer of unknown primary: small steps forward","volume":"49","author":"Riihimaki","year":"2013","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/annonc\/mdr369","article-title":"Power and limits of modern cancer diagnostics: cancer of unknown primary","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol"},{"issue":"47","key":"10.1016\/j.ejca.2018.06.032_bib35","doi-asserted-by":"crossref","first-page":"e2135","DOI":"10.1097\/MD.0000000000002135","article-title":"A simple risk model to predict survival in patients with carcinoma of unknown primary origin","volume":"94","author":"Huang","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"27\u201328","key":"10.1016\/j.ejca.2018.06.032_bib36","first-page":"481","article-title":"Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma","volume":"111","author":"Loffler","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.032_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/0284186X.2013.783230","article-title":"Rapid reduction in the incidence of cancer of unknown primary. A population-based study","volume":"53","author":"Brustugun","year":"2014","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0959-8049(01)00378-1","article-title":"Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992","volume":"38","author":"van de Wouw","year":"2002","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2018.06.032_bib39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-009-9261-5","article-title":"Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis","volume":"28","author":"Adenis","year":"2010","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.ejca.2018.06.032_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/02841861003649240","article-title":"Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site","volume":"49","author":"Moller","year":"2010","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.032_bib41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/PPO.0b013e3181c6aa89","article-title":"Paclitaxel\/carboplatin\/etoposide versus gemcitabine\/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial","volume":"16","author":"Hainsworth","year":"2010","journal-title":"Cancer J"},{"issue":"5","key":"10.1016\/j.ejca.2018.06.032_bib42","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.ijrobp.2009.07.012","article-title":"Radiosurgery for brain metastases from unknown primary cancers","volume":"77","author":"Niranjan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.ejca.2018.06.032_bib43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1159\/000252797","article-title":"Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years","volume":"32","author":"Thom","year":"2009","journal-title":"Onkologie"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.032_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ctrv.2008.10.003","article-title":"Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review","volume":"35","author":"Pentheroudakis","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2018.06.032_bib45","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:14:53Z","timestamp":1661631293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918309468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":45,"alternative-id":["S0959804918309468"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}